Booster dose of new meningitis vaccine may be beneficial

A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age, according to a clinical trial published in CMAJ (Canadian Medical Association Journal).

The 4CMenB , an important breakthrough in the fight against childhood , was recently licensed in Europe and is being considered for approval in Canada and elsewhere. However, although it is known that immunizing infants with the 4CMenB vaccine induces a good immune response (as shown by an increase in antibodies against this bacteria), it was not known how well this response persists through childhood. This is critically important to the potential impact of the vaccine, because children remain at risk from this infection through their preschool years, and even into adolescence.

In this study of 113 children, the Oxford Vaccine Group (part of the University of Oxford Department of Paediatrics) shows that high antibody levels observed 1 month after receiving 4CMenB at 2, 4, 6 and 12 months of age decline over the following 2 ½ years. Blood samples taken from participants were tested against a panel of different strains of the meningitis B bacteria. Against some strains the antibody levels remained higher than in children who had never received the vaccine, while against other strains there was no obvious difference.

"Experience with other meningococcal vaccines has shown that waning of bactericidal antibody titres was associated with a decline in following infant vaccination with serogroup C meningococcal ," writes Dr. Matthew Snape, Department of Pediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK, with coauthors.

After receiving a booster dose at 40 months of age, 89%–100% of the children had high for all but 1 of the 8 Meningitis B strains tested.

"Consistent with other vaccines against meningococcal disease, a waning of hSBA titres was observed after infant vaccination with 4CMenB. A booster dose during preschool years was well tolerated," write the authors.

"If 4CMenB were to be introduced into a routine vaccination schedule, measures such as adequate disease surveillance would be important to determine whether waning of antibodies might influence the effectiveness of a vaccination campaign against this bacterium," they conclude.

More information: Paper: www.cmaj.ca/lookup/doi/10.1503/cmaj.130257

add to favorites email to friend print save as pdf

Related Stories

Meningitis B type vaccine available soon

Jan 20, 2012

(Medical Xpress) -- Researchers in Chile have successfully tested a vaccine against meningococcus B, a strain of bacteria that causes meningococcal diseases, including one of the commonest forms of meningitis, a disease in ...

Effects of meningitis C jab may wear off

Jun 06, 2008

One in five 11–13 year olds appear to have low antibodies against meningitis C after being immunised as young children, suggests an Oxford University study published in the British Medical Journal.

Recommended for you

App for headache sufferers shows success

1 hour ago

A unique app that helps headache sufferers to record the severity and regularity of their pain is being used as part of a Griffith research study.

West African airline suspends flights amid Ebola (Update)

7 hours ago

(AP)—Police officers deployed to Liberia's international airport to ensure passengers are screened for Ebola symptoms as a major regional airline announced Tuesday it was suspending flights to the cities hardest hit by ...

User comments